Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Net Cash Flow (2016 - 2025)

Agios Pharmaceuticals' Net Cash Flow history spans 14 years, with the latest figure at -$3.6 million for Q4 2025.

  • For Q4 2025, Net Cash Flow rose 97.98% year-over-year to -$3.6 million; the TTM value through Dec 2025 reached $12.9 million, up 207.74%, while the annual FY2025 figure was $12.9 million, 207.74% up from the prior year.
  • Net Cash Flow reached -$3.6 million in Q4 2025 per AGIO's latest filing, down from $11.8 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $932.3 million in Q2 2021 to a low of -$1.9 billion in Q4 2021.
  • Average Net Cash Flow over 5 years is -$87.4 million, with a median of -$836500.0 recorded in 2025.
  • The largest YoY upside for Net Cash Flow was 2234.3% in 2021 against a maximum downside of 7474.78% in 2021.
  • A 5-year view of Net Cash Flow shows it stood at -$1.9 billion in 2021, then surged by 100.88% to $16.8 million in 2022, then soared by 42.01% to $23.9 million in 2023, then plummeted by 843.48% to -$177.5 million in 2024, then surged by 97.98% to -$3.6 million in 2025.
  • Per Business Quant, the three most recent readings for AGIO's Net Cash Flow are -$3.6 million (Q4 2025), $11.8 million (Q3 2025), and $1.9 million (Q2 2025).